Incretin-Based Therapies for Type 2 Diabetes

INCRETIN-BASED THERAPIES FOR

TYPE 2 DIABETES Mechanism-Based Strategies to Achieve Patient-Centered Care SEPTEMBER 6, 2013 SEPTEMBER 9, 2013 SEPTEMBER 19, 2013 OCTOBER 8, 2013 OCTOBER 16, 2013 OCTOBER 24, 2013 NOVEMBER 21, 2013 DECEMBER 5, 2013 DECEMBER 10, 2013 This activity is sponsored by

Princeton, New Jersey Denver, Colorado Boston, Massachusetts Tampa, Florida Rosemont, Illinois Raleigh, North Carolina New York, New York Baltimore, Maryland Los Angeles, California

Educational partner pmiCME

This activity is supported by an independent medical education grant from Bristol-Myers Squibb and AstraZeneca LP.

BMS-T2DM Workbook R1 Tampa.indd 2

10/4/13 4:49 PM

BMS-T2DM Workbook R1 Tampa.indd 2

10/4/13 4:49 PM

VIRTUAL PROFESSOR FACULTY

Jack L. Leahy, MD Prerecorded Professor of Medicine Chief, Division of Endocrinology, Diabetes and Metabolism University of Vermont Burlington, Vermont

PRESENTING FACULTY Lawrence Blonde, MD, FACP, FACE Director, Ochsner Diabetes Clinical Research Unit Department of Endocrinology Ochsner Medical Center New Orleans, Louisiana

Richard M. Bergenstal, MD Clinical Professor, Department of Medicine University of Minnesota Executive Director, International Diabetes Center Park Nicollet Minneapolis, Minnesota

Daniel Einhorn, MD, FACE, FACP Clinical Professor of Medicine University of California, San Diego Diabetes and Endocrine Associates Medical Director, Scripps Whittier Diabetes Institute La Jolla, California

Javier Morales, MD Vice President Principal Clinical Trials Investigator Advanced Internal Medicine Group, PC New Hyde Park, New York

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 3

3

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

FACULTY

Richard E. Pratley, MD Samuel E. Crockett, MD, Chair in Diabetes Research Professor, Sanford Burnham Medical Research Institute Medical Director, Florida Hospital Diabetes Institute Senior Scientist, Sanford Burnham Translational Research Institute Orlando, Florida

Mark W. Stolar, MD Associate Professor of Clinical Medicine Northwestern University Feinberg School of Medicine Chicago, Illinois

Jeffrey R. Unger, MD Assistant Professor of Family Medicine Loma Linda University School of Medicine Director of Metabolic Studies Catalina Research Institute Chino, California Not all faculty members will present in all cities. Faculty is subject to change, with additional faculty to be announced. *

4

BMS-T2DM Workbook R1 Tampa.indd 4

10/4/13 4:49 PM

LEARNING OBJECTIVES Upon completion of these educational activities, participants will be better prepared to: • Discuss the multisystem causes and consequences of type 2 diabetes mellitus (T2DM), including pathologic roles of the incretin pathways and the rationale for early diagnosis • Individualize treatment goals for patients with T2DM based on disease duration, age, relevant comorbidities, and ongoing evaluations of hemoglobin A1c levels and therapeutic responses

PREAMBLE

• Evaluate the mechanisms of action and clinical profiles of incretin-based therapies, including glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors • Develop and tailor personalized multimodal treatment plans for T2DM that include lifestyle interventions and incretin-based therapies alone or in combination with other antihyperglycemic medications • Educate diverse populations of patients with T2DM about lifestyle modifications, benefits and risks of various antihyperglycemic medications, and the importance of treatment adherence

TARGET AUDIENCE This activity is intended for primary care providers involved in the treatment and management of patients with type 2 diabetes mellitus.

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 5

5

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

6

BMS-T2DM Workbook R1 Tampa.indd 6

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 7

7

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

8

BMS-T2DM Workbook R1 Tampa.indd 8

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 9

9

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

10

BMS-T2DM Workbook R1 Tampa.indd 10

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 11

11

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

12

BMS-T2DM Workbook R1 Tampa.indd 12

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 13

13

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

14

BMS-T2DM Workbook R1 Tampa.indd 14

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 15

15

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

16

BMS-T2DM Workbook R1 Tampa.indd 16

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 17

17

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

18

BMS-T2DM Workbook R1 Tampa.indd 18

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 19

19

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

20

BMS-T2DM Workbook R1 Tampa.indd 20

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 21

21

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

22

BMS-T2DM Workbook R1 Tampa.indd 22

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 23

23

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

24

BMS-T2DM Workbook R1 Tampa.indd 24

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 25

25

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

26

BMS-T2DM Workbook R1 Tampa.indd 26

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 27

27

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

28

BMS-T2DM Workbook R1 Tampa.indd 28

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 29

29

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

30

BMS-T2DM Workbook R1 Tampa.indd 30

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 31

31

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

32

BMS-T2DM Workbook R1 Tampa.indd 32

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 33

33

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SLIDES

34

BMS-T2DM Workbook R1 Tampa.indd 34

10/4/13 4:49 PM

SLIDES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 35

35

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

SUGGESTED READING LIST American Diabetes Association. Standards of medical care in diabetes--2012. Diabetes Care. 2012;35:S11-S63.

Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819-837.

Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327-336.

Grunberger G. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.

J Diabetes. 2013;5:241-253.

Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011;34(suppl 2):S251-S257.

Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010;33:1759-1765.

Macconell L, Pencek R, Li Y, Maggs D, Porter L. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes. 2013;6:31-41.

SUGGESTED READING

Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med. 2013;125:7-20.

Tschope D, Hanefeld M, Meier JJ, et al. The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes. Cardiovasc Diabetol. 2013;12:62.

Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.

Diabetes Obes Metab. 2013;15:737-749.

36

BMS-T2DM Workbook R1 Tampa.indd 36

10/4/13 4:49 PM

NOTES

Mechanism-Based Strategies to Achieve Patient-Centered Care •

BMS-T2DM Workbook R1 Tampa.indd 37

37

10/4/13 4:49 PM

INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES

NOTES

38

BMS-T2DM Workbook R1 Tampa.indd 38

10/4/13 4:49 PM

BMS-T2DM Workbook R1 Tampa.indd 39

10/4/13 4:49 PM

For more information and to view additional resources for this program, please visit

EXCHANGECME.com/T2DMTHERAPIES

BMS-T2DM Workbook R1 Tampa.indd 1

10/4/13 4:49 PM